Epidarex Captial

Epidarex Capital invests in early-stage, high growth life science and health technology companies in the EU and US. Epidarex was created to meet the need for more sector-specific risk capital for young companies, including spin-outs from leading research universities. The fund’s international management team, has a track record of successfully partnering with top scientists and entrepreneurs to develop highly innovative products for the global healthcare market. For further information, please visit www.epidarex.com

The Latest

Mironid raises $46 million in Series B financing to advance clinical development of its treatment for rare kidney diseaseAugust 5, 2026

Glasgow, Scotland, August 5, 2026 – Mironid, a biopharmaceutical company developing small molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), a life-threatening hereditary kidney disease, today announces it has raised $46 million in a Series B funding round. Neil Wilkie, CEO of Mironid said: “ADPKD is the [...]

Mironid Raises Awareness for PKD with 1,000 km Team ChallengeApril 14, 2026

At Mironid, we’re proud to support causes that make a meaningful difference. Last month, our team took part in the Polycystic Kidney Disease (PKD) Charity UK‘s ‘Spring into March’ challenge, raising awareness and supporting the [...]

Q&A with David Henderson, Head of BiologyMarch 19, 2026

ADPKD is a devastating disease that affects more than 12 million people worldwide. Over the past decade, there has been important progress in our understanding of the disease, with meaningful steps forward for both patients and clinicians. However, significant challenges remain. Tolerability [...]